Evidence map›Paper›PMID 15215131›Full record

ArticleAntimicrobial agents and chemotherapy2004

Purification and characterization of recombinant Staphylococcus haemolyticus DNA gyrase and topoisomerase IV expressed in Escherichia coli.

Joel C Bronstein, Stacey L Olson, Kristin LeVier, Mark Tomilo, Peter C Weber

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joel C BronsteinPfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. Joel.Bronstein@pfizer.com
Stacey L Olson
Kristin LeVier
Mark Tomilo
Peter C Weber
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The subunits of DNA gyrase and topoisomerase IV from Staphylococcus haemolyticus were expressed in Escherichia coli, purified to homogeneity, and used to reconstitute active enzymes that were sensitive to known topoisomerase inhibitors. This represents the first description of a method for isolating type II topoisomerases of a coagulase-negative staphylococcal species.

Indexed as

Anti-Bacterial AgentsDNA GyraseDNA Topoisomerase IVElectrophoresis, Agar GelElectrophoresis, Polyacrylamide GelEnzyme InhibitorsEscherichia coliMolecular Sequence DataRecombinant ProteinsStaphylococcus haemolyticusAnti-Bacterial AgentsDNA GyraseDNA Topoisomerase IVEnzyme InhibitorsRecombinant Proteins

Identifiers

PMID15215131
PMCPMC434177
OpenAlexW2153880231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.